Anti uti drugs pharmacology reference kd Tripathi book mbbs

Reading File

Finding Sources

Reading File

Loading Image

I have all the content needed. Now I'll compile a comprehensive, KD Tripathi-style pharmacology reference on anti-UTI drugs.

Anti-UTI Drugs - Pharmacology (MBBS Reference)

Note: KD Tripathi's Essentials of Medical Pharmacology is not directly in this library, but the content below is drawn from Goodman & Gilman, Katzung, and Lippincott Illustrated Reviews Pharmacology - the three core references that align closely with KD Tripathi's coverage of this topic for MBBS.

Classification of Drugs Used in UTI

I. Urinary Tract Antiseptics (act locally in urine, not systemic infections)

Nitrofurantoin
Methenamine mandelate / Methenamine hippurate
Fosfomycin

II. Systemic Antibiotics Used for UTI

Fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin)
Trimethoprim-Sulfamethoxazole (Co-trimoxazole)
Aminopenicillins (amoxicillin + clavulanate)
Cephalosporins (oral - cephalexin, cefpodoxime)
Aminoglycosides (gentamicin - for complicated/pyelonephritis)

I. URINARY TRACT ANTISEPTICS

A. Nitrofurantoin

Class: Synthetic nitrofuran

Mechanism of Action:

Nitrofurantoin is activated by bacterial reductases (nitroreductases) into highly reactive intermediates
These intermediates damage DNA and also disrupt RNA synthesis and ribosomal proteins (multiple targets)
Bacteria reduce nitrofurantoin much faster than mammalian cells - accounts for selective toxicity
Activity is enhanced in acidic urine (pH < 5.5)

Antimicrobial Spectrum:

Active against: E. coli (most common UTI pathogen), Klebsiella, Enterococcus, Staphylococcus saprophyticus, Enterobacteriaceae
Resistant: Proteus spp., Pseudomonas aeruginosa, many Enterobacter strains
Bacteriostatic at 32 µg/mL; Bactericidal at ≥100 µg/mL

Pharmacokinetics:

Well absorbed orally; macrocrystalline form better tolerated
Two formulations:
- Macrocrystals (Macrodantin): slower absorption, 4x/day
- Macrocrystals + monohydrate (Macrobid): gel matrix, 2x/day
Plasma t½ = 0.3-1 hour - excreted so rapidly that NO systemic antibacterial action achieved
~40% excreted unchanged in urine via glomerular filtration + tubular secretion
Urine concentration: ~200 µg/mL (effective for lower UTI)

Uses:

First-line for uncomplicated cystitis (lower UTI) - 5-7 days course
NOT for pyelonephritis or upper UTI (inadequate tissue levels)
NOT for prostatitis
Prophylaxis of recurrent UTIs: 50-100 mg at bedtime (single daily dose)
Preferred agent in pregnancy (except near term)

Dosage:

Adults: 50-100 mg orally four times daily (macrocrystalline)
OR 100 mg twice daily (macrocrystalline/monohydrate combination)
Children: 5-7 mg/kg/day; 1 mg/kg/day for long-term prophylaxis
Course: max 14 days; do not exceed (risk of toxicity)

Adverse Effects:

System	Effect
GI	Nausea, vomiting, diarrhea (most common; reduced with macrocrystals)
Pulmonary	Pulmonary fibrosis, pneumonitis (prolonged use >1 month)
Neurological	Peripheral neuropathy (prolonged use, renal impairment)
Hematological	Hemolytic anemia (in G6PD deficiency)
Hepatic	Autoimmune hepatitis (rare, chronic use)
Hypersensitivity	Rash, fever, pulmonary infiltrates

Contraindications:

Renal insufficiency (CrCl <60 mL/min traditionally; some allow use if CrCl >30 mL/min for short courses)
G6PD deficiency
Neonates (<1 month) and pregnancy near term (risk of neonatal hemolysis)
Hepatic insufficiency (relative)

Drug Interaction:

Antagonizes the action of nalidixic acid and older fluoroquinolones (norfloxacin, ciprofloxacin)
No cross-resistance with other antimicrobials

B. Methenamine Salts (Methenamine Mandelate / Methenamine Hippurate)

Mechanism of Action: At acidic urine pH ≤ 5.5, methenamine hydrolyzes to release formaldehyde:

N₄(CH₂)₆ + 6H₂O + 4H⁺ → 6HCHO (formaldehyde) + 4NH₄⁺

Formation of formaldehyde from methenamine at acidic pH

Formaldehyde denatures proteins and nucleic acids - bactericidal
At pH 7.4: almost no decomposition; at pH 5: 6% yield; at pH 5: 20% yield
Reaction requires ~3 hours to reach 90% completion
Combined with a weak acid (mandelic acid or hippuric acid) to maintain urinary acidity
No resistance develops to formaldehyde - key advantage

Two formulations:

Methenamine mandelate (salt of mandelic acid): mandelic acid itself is also antibacterial
Methenamine hippurate (salt of hippuric acid): preferred in renal insufficiency (mandelic acid may precipitate in renal failure)

Antibacterial Spectrum:

E. coli, Enterococcus, Staphylococcus
Proteus spp. are relatively resistant - they produce urease, raising urine pH, thus preventing formaldehyde release
Pseudomonas: some activity if urine is kept acidic
Key advantage: does NOT select for resistant organisms

Pharmacokinetics:

Orally absorbed; up to 30% decomposed by gastric acid (enteric coating prevents this)
Excreted via tubular secretion + glomerular filtration
Avoid in hepatic insufficiency (ammonia released during hydrolysis)

Uses:

Chronic suppressive therapy (long-term prophylaxis) to reduce frequency of recurrent UTIs
NOT appropriate for acute UTI treatment
Requires maintenance of urine pH <5.5 for efficacy (use acidifying agents: ascorbic acid, ammonium chloride)

Adverse Effects:

GI distress (most common)
High doses: albuminuria, hematuria, rash
Methenamine mandelate: contraindicated in renal insufficiency (mandelic acid precipitates)

Important Interaction:

Do NOT combine with sulfonamides (TMP/SMX): increases risk of crystalluria and mutual antagonism

C. Fosfomycin

Class: Phosphonic acid derivative (synthetic)

Mechanism of Action:

Inhibits MurA (enolpyruvyl transferase) - the enzyme catalyzing the first step in bacterial cell wall (peptidoglycan) synthesis
This mechanism is unique among antibacterials - no cross-resistance with other drugs
Also reduces bacterial adherence to urothelial cells
Bactericidal

Antimicrobial Spectrum:

E. coli, Proteus, Enterococcus, S. saprophyticus (common uropathogens)
Variable: Klebsiella, Enterobacter, Serratia
Resistant: Pseudomonas, Acinetobacter

Pharmacokinetics:

Oral form only available in most countries (fosfomycin tromethamine - dissolved powder)
Oral bioavailability ~40%; t½ = 5-8 hours
After 3 g oral dose: urine concentration = 1000-4000 µg/mL (very high)
Systemic levels are low - action confined to urinary tract

Uses:

First-line for uncomplicated acute cystitis - single 3 g oral dose (major advantage: single-dose regimen = excellent compliance)
Prophylaxis: 3 g every 10 days
Complicated UTI: 3 g every other day × 3 doses

Adverse Effects:

Well tolerated overall
GI distress, vaginitis, headache, dizziness (all uncommon)

II. SYSTEMIC ANTIBIOTICS FOR UTI

A. Fluoroquinolones (Ciprofloxacin, Norfloxacin, Ofloxacin, Levofloxacin)

Mechanism: Inhibit DNA gyrase (in gram-negatives) and Topoisomerase IV (in gram-positives) → bactericidal

Uses in UTI:

Uncomplicated and complicated UTIs, pyelonephritis
Norfloxacin is concentrated in urine - primarily used for UTI
Ciprofloxacin/Levofloxacin - used for pyelonephritis, complicated UTIs, prostatitis

Note (KD Tripathi-important): Due to increasing resistance in E. coli and FDA warnings (tendinopathy, CNS effects, peripheral neuropathy), fluoroquinolones should be reserved for UTIs where alternatives are unsuitable.

Adverse effects: Nausea, photosensitivity, QT prolongation, tendinitis/tendon rupture (boxed warning), peripheral neuropathy, CNS effects

B. Trimethoprim-Sulfamethoxazole (Co-trimoxazole / TMP-SMX)

Mechanism: Sequential blockade of folate synthesis

Sulfamethoxazole blocks dihydropteroate synthase (inhibits PABA incorporation)
Trimethoprim blocks dihydrofolate reductase
Combined: synergistic bactericidal action

Uses: Uncomplicated UTI - standard 3-day course for cystitis

Avoid if: Local E. coli resistance >20% (check antibiogram); renal failure; G6PD deficiency (sulfa component); folate deficiency; pregnancy (3rd trimester)

Key interactions: Do NOT combine with methenamine (crystalluria risk)

Summary Table: UTI Drugs at a Glance

Drug	MOA	Use	Key ADR	Key CI
Nitrofurantoin	Reactive intermediates → DNA/RNA damage	Uncomplicated cystitis, prophylaxis	Pulmonary fibrosis, neuropathy, hemolytic anemia (G6PD)	Renal failure, G6PD deficiency, neonates
Methenamine	Formaldehyde at pH <5.5 → protein denaturation	Long-term suppression/prophylaxis	GI distress, hematuria	Renal failure (mandelate), hepatic failure
Fosfomycin	Inhibits MurA → blocks cell wall synthesis	Acute cystitis (single dose)	GI distress (mild)	Rarely contraindicated
Fluoroquinolones	DNA gyrase/Topo IV inhibition	Complicated UTI, pyelonephritis, prostatitis	Tendinopathy, QT prolongation, neuropathy	Reserved - not first-line
TMP-SMX	Sequential folate blockade	Uncomplicated cystitis (3-day)	Crystalluria, hematotoxicity	Resistance >20%, G6PD deficiency

Mnemonics for MBBS Exams

Drugs NOT for upper UTI/pyelonephritis:

"Nitro Methane Fog" = Nitrofurantoin, Methenamine, Fosfomycin (all confined to lower urinary tract - do NOT use for pyelonephritis)

Nitrofurantoin ADRs - "P-N-H-G":

Pulmonary fibrosis, Neuropathy, Hemolytic anemia (G6PD), GI distress

Methenamine needs acidic urine (pH <5.5):

Proteus raises pH by urease → methenamine fails against Proteus

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, 14e, p.1193; Katzung's Basic and Clinical Pharmacology, 16e, p.1395; Lippincott Illustrated Reviews Pharmacology, 8e, p.1043-1046

Anti utdrugs pharmacology reference kd Tripathi book mbbs

Reading File

This is the same question as before - I already have all the content from the previous session. Let me deliver the complete answer directly.

Anti-UTI Drugs - Pharmacology (MBBS / KD Tripathi Style)

Note: KD Tripathi's Essentials of Medical Pharmacology is not directly available in this library, but the content below is compiled from Goodman & Gilman, Katzung's Basic & Clinical Pharmacology (16e), and Lippincott Illustrated Reviews Pharmacology - the exact same topics KD Tripathi covers, in the same MBBS-oriented style.

Classification of Anti-UTI Drugs

A. Urinary Tract Antiseptics (act locally in urine, NOT systemic infections)

Nitrofurantoin
Methenamine mandelate / Methenamine hippurate
Fosfomycin

B. Systemic Antibiotics Used for UTI

Fluoroquinolones - Norfloxacin, Ciprofloxacin, Ofloxacin, Levofloxacin
Trimethoprim-Sulfamethoxazole (Co-trimoxazole / TMP-SMX)
Aminopenicillins - Amoxicillin + Clavulanate
Oral Cephalosporins - Cephalexin, Cefpodoxime
Aminoglycosides - Gentamicin (complicated UTI / pyelonephritis)

PART I - URINARY TRACT ANTISEPTICS

1. NITROFURANTOIN

Mechanism of Action

Nitrofurantoin is activated by bacterial nitroreductases into highly reactive intermediates
These intermediates cause DNA strand breakage, inhibit RNA synthesis, and disrupt multiple ribosomal proteins
Bacteria reduce nitrofurantoin far more rapidly than mammalian cells - basis of selective toxicity
Antibacterial activity is greatly enhanced in acidic urine (pH < 5.5)

Antimicrobial Spectrum

Sensitive: E. coli (most common UTI pathogen), Klebsiella, Enterococcus, Staphylococcus saprophyticus, Enterobacteriaceae
Resistant: Proteus spp., Pseudomonas aeruginosa, many Enterobacter strains
Bacteriostatic at 32 µg/mL; Bactericidal at ≥100 µg/mL
No cross-resistance with any other antimicrobial class

Pharmacokinetics

Parameter	Detail
Absorption	Rapid and complete oral absorption
Distribution	Rapid elimination - NO systemic antibacterial action
t½	0.3-1 hour (very short)
Urine concentration	~200 µg/mL (adequate for lower UTI)
Excretion	~40% unchanged in urine via GFR + tubular secretion

Formulations:

Macrocrystals (Macrodantin): slower dissolution, 4 times/day dosing
Macrocrystals + monohydrate combination (Macrobid): gel matrix → twice daily dosing, better tolerated

Therapeutic Uses

First-line for uncomplicated cystitis (lower UTI) - 5 to 7 day course
Prophylaxis of recurrent UTIs: 50-100 mg single dose at bedtime
Preferred in pregnancy (except near-term/at term)
NOT for pyelonephritis - inadequate tissue/renal parenchymal levels
NOT for prostatitis - does not penetrate prostatic tissue

Dosage

Adults: 100 mg orally 4 times daily (macrocrystals) OR 100 mg twice daily (combination form)
Children: 5-7 mg/kg/day in divided doses; 1 mg/kg/day for long-term prophylaxis
Maximum course: 14 days; repeated courses separated by rest periods

Adverse Effects

System	Effect
GI (most common)	Nausea, vomiting, diarrhea - less with macrocrystals
Pulmonary	Pulmonary fibrosis, pneumonitis (prolonged use >1 month)
Neurological	Peripheral neuropathy (prolonged use, especially with renal impairment)
Hematological	Hemolytic anemia in G6PD deficiency
Hepatic	Autoimmune hepatitis (rare, chronic use)
Hypersensitivity	Rash, fever, pulmonary infiltrates

Contraindications

Renal insufficiency (CrCl <60 mL/min - traditionally; avoid in significant renal failure)
G6PD deficiency
Neonates (<1 month) and pregnancy at/near term (risk of neonatal hemolytic anemia)
Hepatic insufficiency

Drug Interaction

Antagonizes the action of nalidixic acid and some fluoroquinolones (norfloxacin, ciprofloxacin)

2. METHENAMINE SALTS

Available as:

Methenamine mandelate (salt of mandelic acid)
Methenamine hippurate (salt of hippuric acid)

Mechanism of Action

At urine pH ≤ 5.5, methenamine is hydrolyzed to release formaldehyde:

N₄(CH₂)₆ + 6H₂O + 4H⁺ → 6 HCHO (formaldehyde) + 4NH₄⁺

Methenamine decomposition to formaldehyde at acidic pH - kills bacteria

Formaldehyde denatures proteins and nucleic acids → bactericidal
At pH 7.4: almost no decomposition; at pH 6: only 6% yield; at pH 5: 20% yield
Hydrolysis reaction takes ~3 hours to reach 90% completion
No organism develops resistance to formaldehyde - key long-term advantage
Combined with mandelic acid or hippuric acid to keep urine pH acidic

Why Proteus is Resistant

Proteus spp. produce urease → splits urea → raises urine pH → prevents formaldehyde release → drug fails

Pharmacokinetics

Orally absorbed; enteric coating prevents ~30% gastric decomposition
Excreted via GFR + tubular secretion into urine
Avoid in hepatic failure (ammonia released during hydrolysis can cause encephalopathy)

Therapeutic Uses

Long-term suppressive/prophylactic therapy for recurrent UTIs
NOT suitable for acute UTI treatment (slow onset, requires acidic urine maintenance)
Needs concurrent urinary acidification (ascorbic acid, ammonium chloride)

Adverse Effects

GI distress (most common)
Higher doses: albuminuria, hematuria, rash
Methenamine mandelate - contraindicated in renal failure (mandelic acid precipitates)
Methenamine hippurate - safer in renal insufficiency

Important Drug Interaction

Do NOT combine with sulfonamides (TMP-SMX): mutual antagonism + increased risk of crystalluria

3. FOSFOMYCIN

Mechanism of Action

Inhibits MurA (enolpyruvyl transferase) - enzyme catalyzing the first step in peptidoglycan (cell wall) synthesis
This target is unique - no cross-resistance with any other antibiotic class
Also reduces bacterial adherence to urothelial epithelium
Bactericidal

Antimicrobial Spectrum

Sensitive: E. coli, Proteus, Enterococcus, S. saprophyticus
Variable: Klebsiella, Enterobacter, Serratia
Resistant: Pseudomonas aeruginosa, Acinetobacter

Pharmacokinetics

Parameter	Detail
Form	Fosfomycin tromethamine - oral powder dissolved in water
Bioavailability	~40%
t½	5-8 hours
Urine concentration	1000-4000 µg/mL after single 3 g dose (very high)
Systemic levels	Low - action confined to urinary tract

Therapeutic Uses

First-line for uncomplicated acute cystitis - SINGLE 3 g oral dose (best compliance)
Complicated UTI: 3 g every other day × 3 doses
Prophylaxis: 3 g every 10 days

Adverse Effects

Well-tolerated overall
Mild GI distress, vaginitis, headache, dizziness (all uncommon)

PART II - SYSTEMIC ANTIBIOTICS FOR UTI

4. FLUOROQUINOLONES

Examples: Norfloxacin, Ciprofloxacin, Ofloxacin, Levofloxacin

Mechanism: Inhibit DNA gyrase (gram-negatives) and Topoisomerase IV (gram-positives) → bactericidal

Drug	Main UTI Use
Norfloxacin	Uncomplicated UTI (concentrates in urine)
Ciprofloxacin	Complicated UTI, pyelonephritis, prostatitis
Levofloxacin	Pyelonephritis, complicated UTI

Current Status (KD Tripathi important point): Increasing resistance in E. coli + FDA boxed warnings (tendinopathy, peripheral neuropathy, CNS effects) mean fluoroquinolones are now reserved - not first-line for simple UTIs. Use when alternatives are unsuitable.

Adverse effects: Nausea, photosensitivity, QT prolongation, tendinitis/tendon rupture, peripheral neuropathy

5. TRIMETHOPRIM-SULFAMETHOXAZOLE (Co-trimoxazole / TMP-SMX)

Mechanism: Sequential blockade of folate synthesis

Sulfamethoxazole → inhibits dihydropteroate synthase (blocks PABA incorporation)
Trimethoprim → inhibits dihydrofolate reductase
Combined effect: synergistic bactericidal action

Use: Uncomplicated UTI - standard 3-day course for cystitis

Avoid when:

Local E. coli resistance >20% (check local antibiogram)
Renal failure, G6PD deficiency, pregnancy (3rd trimester), folate deficiency
Never combine with methenamine (crystalluria + antagonism)

Summary Comparison Table

Drug	Class	MOA	Primary Use	Key ADR	Key CI
Nitrofurantoin	Nitrofuran	Reactive intermediates → DNA/RNA damage	Uncomplicated cystitis, prophylaxis	Pulmonary fibrosis, neuropathy, hemolysis (G6PD)	Renal failure, G6PD-def
Methenamine	Urinary antiseptic	Formaldehyde at pH <5.5 → protein denaturation	Long-term UTI suppression/prophylaxis	GI distress, hematuria	Hepatic failure, renal failure (mandelate)
Fosfomycin	Phosphonic acid	Inhibits MurA → blocks cell wall synthesis	Acute cystitis (single dose)	Mild GI only	Rarely
Fluoroquinolones	Quinolone	DNA gyrase/Topo IV inhibition	Complicated UTI, pyelonephritis, prostatitis	Tendinopathy, QT prolongation, neuropathy	Pregnancy, children (relative)
TMP-SMX	Antifolate	Sequential folate blockade	Uncomplicated cystitis (3-day)	Crystalluria, rash, hematotoxicity	Resistance >20%, G6PD-def

High-Yield Exam Points (KD Tripathi Style)

1. Drugs ONLY for lower UTI (NOT pyelonephritis):

Nitrofurantoin, Methenamine, Fosfomycin - all three fail to achieve adequate tissue levels in renal parenchyma

2. Drug of choice - uncomplicated cystitis:

Nitrofurantoin (5-7 days) OR Fosfomycin (single dose) OR TMP-SMX (3 days) - all first-line

3. Drug of choice - recurrent UTI prophylaxis:

Nitrofurantoin (50-100 mg at bedtime) or Methenamine (long-term suppression)

4. Nitrofurantoin ADR mnemonic - "PNHG":

Pulmonary fibrosis, Neuropathy, Hemolytic anemia (G6PD), GI distress

5. Methenamine mechanism key points:

Needs pH <5.5 | Fails against Proteus (urease raises pH) | No resistance develops | Do NOT combine with sulfonamides

6. Fosfomycin unique features:

Single-dose regimen | Unique MOA (MurA inhibition) | No cross-resistance | Also active against Proteus (unlike nitrofurantoin)

7. Fluoroquinolone for prostatitis:

Trimethoprim and fluoroquinolones concentrate in prostatic fluid - preferred for bacterial prostatitis

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics, 14e - Katzung's Basic & Clinical Pharmacology, 16e - Lippincott Illustrated Reviews Pharmacology, 8e (pp. 1043-1046)

This is a shared conversation. Sign in to Orris to start your own chat.